CN112438921A - Composition for improving skin beauty comprising fermented notoginseng root extract obtained from aspergillus papulosus - Google Patents
Composition for improving skin beauty comprising fermented notoginseng root extract obtained from aspergillus papulosus Download PDFInfo
- Publication number
- CN112438921A CN112438921A CN202010275128.4A CN202010275128A CN112438921A CN 112438921 A CN112438921 A CN 112438921A CN 202010275128 A CN202010275128 A CN 202010275128A CN 112438921 A CN112438921 A CN 112438921A
- Authority
- CN
- China
- Prior art keywords
- composition
- fermented
- notoginseng root
- extract
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000180649 Panax notoginseng Species 0.000 title claims abstract description 119
- 235000003143 Panax notoginseng Nutrition 0.000 title claims abstract description 119
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 241000228212 Aspergillus Species 0.000 title claims abstract description 23
- 230000003796 beauty Effects 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 39
- 238000000855 fermentation Methods 0.000 claims abstract description 38
- 230000004151 fermentation Effects 0.000 claims abstract description 38
- 230000037303 wrinkles Effects 0.000 claims abstract description 16
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 230000009759 skin aging Effects 0.000 claims abstract description 11
- 230000037394 skin elasticity Effects 0.000 claims abstract description 10
- 239000007787 solid Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000006210 lotion Substances 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- 102000016942 Elastin Human genes 0.000 claims description 7
- 108010014258 Elastin Proteins 0.000 claims description 7
- 229920002549 elastin Polymers 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 235000015097 nutrients Nutrition 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 4
- 239000008267 milk Substances 0.000 claims description 4
- 210000004080 milk Anatomy 0.000 claims description 4
- 230000003020 moisturizing effect Effects 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229940064222 panax notoginseng root extract Drugs 0.000 claims 3
- 238000004140 cleaning Methods 0.000 claims 1
- 239000000469 ethanolic extract Substances 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 238000009499 grossing Methods 0.000 claims 1
- 239000008269 hand cream Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 241001205401 Aspergillus cristatus Species 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 15
- 230000002401 inhibitory effect Effects 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 52
- 230000000052 comparative effect Effects 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 238000000605 extraction Methods 0.000 description 21
- 238000010563 solid-state fermentation Methods 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 230000002500 effect on skin Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 102100031509 Fibrillin-1 Human genes 0.000 description 10
- 101000846893 Homo sapiens Fibrillin-1 Proteins 0.000 description 10
- 241001122767 Theaceae Species 0.000 description 10
- 235000013616 tea Nutrition 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000011449 brick Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 102100033167 Elastin Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- -1 foundations Substances 0.000 description 6
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 235000019225 fermented tea Nutrition 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 108020004635 Complementary DNA Proteins 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000002037 dichloromethane fraction Substances 0.000 description 3
- 239000002038 ethyl acetate fraction Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940107131 ginseng root Drugs 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001965 potato dextrose agar Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 2
- 108010051457 Acid Phosphatase Proteins 0.000 description 2
- 102000013563 Acid Phosphatase Human genes 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101710180684 Beta-hexosaminidase Proteins 0.000 description 2
- 101710124976 Beta-hexosaminidase A Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 108010030229 Fibrillin-1 Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 2
- 101710081801 Protein O-GlcNAcase Proteins 0.000 description 2
- 101710199095 Putative beta-hexosaminidase Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000006096 absorbing agent Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 102000005840 alpha-Galactosidase Human genes 0.000 description 2
- 108010030291 alpha-Galactosidase Proteins 0.000 description 2
- 102000019199 alpha-Mannosidase Human genes 0.000 description 2
- 108010012864 alpha-Mannosidase Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 2
- 102000006995 beta-Glucosidase Human genes 0.000 description 2
- 108010047754 beta-Glucosidase Proteins 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000729173 Cirsium japonicum Species 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241001136487 Eurotium Species 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- XBJFCYDKBDVADW-UHFFFAOYSA-N acetonitrile;formic acid Chemical compound CC#N.OC=O XBJFCYDKBDVADW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229940067599 ascorbyl glucoside Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 229920001512 foam latex Polymers 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229940078752 magnesium ascorbyl phosphate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012860 organic pigment Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- HTJNEBVCZXHBNJ-XCTPRCOBSA-H trimagnesium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;diphosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.OC[C@H](O)[C@H]1OC(=O)C(O)=C1O HTJNEBVCZXHBNJ-XCTPRCOBSA-H 0.000 description 1
- 229960005066 trisodium edetate Drugs 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Biotechnology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The present invention relates to a composition for improving skin beauty comprising a fermented notoginseng root extract obtained by fermentation with a novel Aspergillus cristatus strain, and a method for preparing the same. According to the composition for improving skin beauty in one aspect of the present invention, the fermented notoginseng root extract fermented with the strain of aspergillus coronarius has the effects of improving skin wrinkles, enhancing skin elasticity and inhibiting skin aging, and thus is useful for improving skin beauty. According to the method for preparing the notoginseng root extract according to another aspect of the present invention, the fermented notoginseng root extract having the effect of improving skin beauty can be prepared, and the prepared extract can be applied to various fields such as cosmetics and foods.
Description
Cross Reference to Related Applications
This application claims priority and benefit from korean patent application No. 10-2019-0105186, filed on 27.08.2019, which is incorporated herein by reference for all purposes as if fully set forth herein.
Technical Field
The present invention relates to a composition for improving skin beauty comprising a fermented notoginseng root extract.
Background
With age, human skin is affected by a number of intrinsic and extrinsic factors. That is, in an intrinsic aspect, since secretion of various hormones regulating metabolism is decreased and functions and cellular activities of immune cells are decreased, biosynthesis of immune proteins and organism constituent proteins required for a human body is decreased. Externally, the ultraviolet content reaching the earth surface from the sun increases due to the destruction of the ozone layer, and as environmental pollution progresses, radicals, active oxygen, and the like increase, causing various changes, for example, not only a decrease in the thickness of the skin, an increase in wrinkles, a decrease in elasticity, but also a darkening of the skin color, frequently causing problems in the skin, and an increase in moles, freckles, age spots, and the like.
The phenomena of wrinkles and decreased elasticity of the skin, drooping and dryness of the skin, etc., which generally occur in aged skin, are caused by the change or decrease in the content and arrangement of substances constituting the skin (e.g., collagen, elastin, hyaluronic acid and glycoprotein), and particularly, collagen has a function of controlling the tension and strength of the skin, so that the decrease of collagen has a very deep relationship with the aging of the skin and the formation of wrinkles. In addition, as the dermis functions in the skin to support the strength and morphology of the skin, changes in the dermis morphology play a critical role in wrinkle formation and skin sloughing as aging progresses. Therefore, a substance increasing dermal components such as collagen and elastin can be effectively applied to improve skin wrinkles, inhibit skin aging, or enhance skin elasticity.
On the other hand, Aspergillus cristatus (Aspergillus cristatus) is a microorganism that is dominant in fu zhu an brick tea (Fuzhuan brick tea) as post fermented tea (post fermented tea) in china, and is also called Golden flower Fungus (Golden flower Fungus) by chinese because it forms spores such as Golden flower. Eurotium cristatus (a. cristatus) is a safe strain that does not produce carcinogenic mycotoxins, and has been used in brick tea production for a long time. In addition, it was also reported that the presence and expression of mycotoxin genes were not observed in eurotium cristatum (a. cristatus) isolated from fu brick tea by Yongyi Ge et al (2016).
The Notoginseng radix root is root of Panax notoginseng (Burk) F.H.Chen) belonging to Araliaceae. Notoginseng radix has the effects of stopping bleeding and removing blood stasis, and can be used for treating various bleeding syndromes, such as hematemesis, epistaxis, hemoptysis, hematochezia, contusion, fracture, blood stasis, abdominal pain, abscess, pain, puerperal hemorrhage, etc. Pharmacological effects have been reported to include shortening of blood coagulation time, anti-fatigue effect, lowering of blood pressure, lowering of heart rate, increase of coronary blood flow, lipolysis, enhancement of liver function, activation of immune function, and the like.
Research is being conducted to find and develop food or cosmetic materials from natural products that have been used for a long period of time and have less side effects, but research on fermented notoginseng roots as a material is rare.
[ Prior Art document ]
[ patent document ]
(patent document 0001) korean registered patent No. 10-1419463.
[ non-patent literature ]
(non-patent document 0001) Youngyi Ge et al, "synthetic genetic and transfer microorganisms analytes of the fuzzy brick tea-transfer fungus Aspergillus cristatus", BMC genetics (2016) 17: 428.
disclosure of Invention
An aspect of the present invention provides a cosmetic composition for improving skin beauty, comprising a fermented notoginseng root extract obtained by fermenting notoginseng root using Aspergillus cristatus (Aspergillus cristatus) strain as an effective ingredient.
Another aspect of the present invention provides a food composition for improving skin beauty, comprising a fermented notoginseng root extract obtained by fermenting notoginseng root using Aspergillus cristatus (Aspergillus cristatus) strain as an effective ingredient.
Another aspect of the present invention also provides a method for preparing a fermented notoginseng root extract, which comprises: fermenting Notoginseng radix with Monascus coronarius strain to obtain fermented Notoginseng radix; and contacting the fermented notoginseng root with a C1-C6 alcohol, water or a mixture thereof.
An aspect of the present invention provides a cosmetic composition for improving skin beauty, comprising a fermented notoginseng root extract obtained by fermenting notoginseng root using Aspergillus cristatus (Aspergillus cristatus) strain as an effective ingredient.
The skin beautifying improving agent can be used for improving skin wrinkles, enhancing skin elasticity or inhibiting skin aging.
The term "improving skin wrinkles" or "enhancing skin elasticity" may refer to alleviating the degree of sagging or sagging of the skin, reducing or inhibiting the formation of skin wrinkles, or improving already formed wrinkles.
The term "improvement" may refer to the alleviation of the condition or at least all actions that reduce a treatment-related parameter, such as the degree of symptoms.
The term "inhibiting skin aging" may refer to inhibiting or delaying aging of the skin, regardless of the cause of aging.
The "Aspergillus cristatus" is an Aspergillus species which forms spores like the golden flower and is therefore also called golden flower fungus (golden flower fungus). The aspergillus guani (a. cristatus) may be, but not limited to, isolated from food, soil, sea, etc., and may be, for example, isolated from fu zhuan brick tea (Fuzhuan brick tea) which is post fermented tea (post fermented tea) in china.
In the composition according to an embodiment, the strain may be Aspergillus cristatus (GF 8 strain) (accession No.: KCCM 12432P). The aspergillus guani GF8 strain is a novel strain separated from Fuzhuan tea prepared from China, and particularly can be a strain separated by a method comprising the following steps: diluting Fuzhuan tea by using a sodium chloride solution; culturing the diluted Fuzhuan tea in potato dextrose agar medium supplemented with chloramphenicol (chloremphenicol); and screening the strains forming golden colonies in the medium. The concentration of the sodium chloride solution can be 0.50% (w/w) to 0.99% (w/w), 0.60% (w/w) to 0.95% (w/w), 0.70% (w/w) to 0.90% (w/w), 0.80% (w/w) to 0.90% (w/w), 0.84% (w/w) to 0.86% (w/w) (e.g., 0.85% (w/w)). The culturing may be carried out at a temperature of 20 ℃ to 40 ℃, 25 ℃ to 35 ℃, 27 ℃ to 35 ℃, 28 ℃ to 32 ℃. The culturing may be performed for 10 hours to 100 hours, 20 hours to 90 hours, 30 hours to 80 hours, 40 hours to 70 hours, 48 hours to 65 hours, 48 hours to 60 hours.
The Notoginseng radix root is root of Panax notoginseng (Burk) F.H.Chen) belonging to Araliaceae family. The notoginseng root can be obtained by a conventional method, for example, by purchasing a product sold in the market. The notoginseng root may be sterilized notoginseng root, and the sterilization method may be performed by a conventional method in the art.
In a composition according to a particular embodiment, the fermentation may be a solid fermentation. The term "solid fermentation" may refer to fermentation performed by inoculating a microorganism to a raw material having a solid state of low moisture. The solid fermentation method has advantages in that it is not contaminated with various bacteria and the product can be easily recovered, compared to the existing fermentation methods such as a liquid fermentation method or a semi-solid fermentation method.
In the composition according to a specific embodiment, the fermented notoginseng root may be subjected to solid fermentation by inoculating a aspergillus guani (a. cristatus), specifically, a suspension of spores of the aspergillus guani (a. cristatus), to the notoginseng root.
In the composition according to a specific embodiment, the culture substrate may be converted into a functional substance by the extracellular enzyme (extracellular enzyme) of aspergillus papulosus (a. cristatus) through the fermentation. The kind of the extracellular enzyme may include, for example, Alkaline phosphatase (alkali phosphatase), Esterase (C4)), Esterase Lipase (C8)), Acid phosphatase (Acid phosphatase), α -galactosidase (alpha-galactosidase), β -galactosidase (beta-galactosidase), β -glucosidase (beta-glucosidase), N-acetyl- β -glucosaminidase (N-acetyl-beta-glucosaminidase), α -mannosidase (alpha-mannosidase), and the like, but is not limited thereto. Therefore, it is important to maintain a phase (phase) of conversion from hyphae to spores, which is the highest point of the enzyme biosynthesis amount in the life cycle (life cycle) of aspergillus guani (a. cristatus), for a long time. Therefore, in order to maximally maintain the stage of high extracellular enzyme expression of aspergillus papulosus (a. cristatus) and increase useful components of notoginseng root, appropriate fermentation temperature, time, and the like may be selected.
The fermented notoginseng root can be fermented at a temperature of 25 ℃ to 40 ℃, 25 ℃ to 35 ℃, 25 ℃ to 32 ℃, 28 ℃ to 40 ℃, 28 ℃ to 35 ℃, 28 ℃ to 32 ℃ or 30 ℃. When the fermentation temperature exceeds 35 ℃, the activity and expression amount of the enzyme may be relatively decreased because the time required for the strain to sporulate becomes shorter, and on the contrary, when the fermentation temperature is lower than 25 ℃, the conversion rate to the functional ingredient may be decreased because the reaction rate of the enzyme is slowed down.
The fermented notoginseng root may be fermented for 0.5 to 20 days, 1 to 20 days, 1.5 to 20 days, 2.5 to 20 days, 3 to 20 days, 0.5 to 10 days, 1 to 10 days, 1.5 to 10 days, 2.5 to 10 days, 3 to 10 days, 0.5 to 9 days, 1 to 9 days, 1.5 to 9 days, 2.5 to 9 days, 3 to 9 days, 0.5 to 7.5 days, 1 to 7.5 days, 1.5 to 7.5 days, 2.5 to 7.5 days, 3 to 7.5 days, 0.5 to 7 days, 1 to 7 days, 1.5 to 7 days, 2.5 to 7 days, 3 to 7 days, or 4 to 6 days. The fermentation time may be appropriately selected in consideration of the growth of hyphae depending on the fermentation temperature so as to terminate before sporulation.
For example, the fermented notoginseng root may be fermented at 25 to 35 ℃ for 1 to 10 days.
The fermented notoginseng root may be the whole of, a part of, or a material derived from the fermented notoginseng root. The fermented notoginseng root used for extraction may be obtained by grinding or fine-cutting or appropriately drying the whole, a part thereof or a material derived therefrom. The fermented notoginseng root having a moisture content of 20% or less and 15% or less (for example, 12% or less) after drying can be used.
The extract can be extracted by using a hydrophilic solvent such as alcohol, water or a combination thereof. The alcohol may be a compound having at least one-OH group of C1 to C10. The alcohol may be a C1 to C6 alcohol, a C3 to C6 polyol. The alcohol can be methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, isobutanol, tert-butanol, n-pentanol, n-hexanol, or mixtures thereof. The solvent may be, for example, a mixture of water and alcohol, i.e., an aqueous alcohol solution. The alcohol concentration of the alcohol aqueous solution may be 1% (w/w) to 100% (w/w), for example, 1% (w/w) to 99.5% (w/w), 10% (w/w) to 100% (w/w), 20% (w/w) to 100% (w/w), 30% (w/w) to 100% (w/w), 40% (w/w) to 100% (w/w), 50% (w/w) to 100% (w/w), 60% (w/w) to 100% (w/w), 70% (w/w) to 100% (w/w), 75% (w/w) to 100% (w/w), 60% (w/w) to 90% (w/w), 70% (w/w) to 90% (w/w), 75% (w/w) to 85% (w/w), or 80% (w/w). The alcohol aqueous solution may be a methanol aqueous solution, an ethanol aqueous solution, or a butanol aqueous solution. In a composition according to a particular embodiment, the extract may be an alcoholic extract.
The extract may be extracted by a conventional method in the art, such as heat extraction, pressure extraction, ultrasonic extraction, hot water extraction, reflux cooling extraction, subcritical extraction or supercritical extraction, etc. For example, the extraction solvent may be added to the whole, a part of, or a material derived from the fermented notoginseng root and subjected to sonication, followed by stirring in a rotary shaker.
The extraction solvent may be 0.5 to 10 (v/w), 0.8 to 10 (v/w), 0.5 to 5 (v/w), 0.8 to 5 (v/w), 0.5 to 3 (v/w), 0.8 to 3 (v/w), 0.5 to 2 (v/w), 0.8 to 2 (v/w), 0.5 to 1.5 (v/w) or 1 (v/w) times of the fermented notoginseng root. For example, it may include adding 50L to 50mL of the extraction solvent to 100g of the fermented notoginseng root as a whole, a part thereof, or a material derived therefrom.
The extraction time may be appropriately selected according to the selected temperature and extraction method. For example, the extraction time may be 1 hour to 3 days, 1 hour to 2 days, 1 hour to 1 day, 5 hours to 3 days, 5 hours to 2 days, 5 hours to 1 day, 10 hours to 3 days, 15 hours to 2 days, 15 hours to 36 hours, 18 hours to 30 hours, 1 day to 3 days, 1 day to 2 days, or 24 hours. For example, the extraction may be performed by stirring in a rotary shaker for 24 hours after adding an extraction solvent to the whole of the fermented notoginseng root, a part thereof, or a material derived therefrom and performing sonication for 10 minutes. The extraction may be more than one extraction, for example, 1 to 5, 1 to 4, 1 to 3, 2 to 5, or 2 to 4 extractions, each of which may be performed in the same method or in a different method.
The extraction may be by known methods such as filtration to separate the plant residue from the extraction liquid. The extraction may also include removing the solvent from the resulting extract by known methods such as concentration under reduced pressure. The extraction may also include preparing the resulting extract into a dried extract by drying, such as freeze drying.
The extract may be present in an amount of 0.001% to 80%, for example, 0.001% to 60%, 0.001% to 40%, 0.001% to 30%, 0.001% to 20%, 0.001% to 10%, 0.001% to 5%, 0.01% to 60%, 0.01% to 40%, 0.01% to 30%, 0.01% to 20%, 0.01% to 10%, 0.01% to 5%, 0.05% to 60%, 0.05% to 40%, 0.05% to 30%, 0.05% to 20%, 0.05% to 10%, 0.05% to 5%, 0.1% to 60%, 0.1% to 40%, 0.1% to 30%, 0.1% to 20%, 0.1% to 10%, or 0.1% to 5%, based on the total weight of the composition.
The composition according to an embodiment may include a fraction of the fermented notoginseng root extract instead of the fermented notoginseng root extract as an effective ingredient. The composition according to an embodiment may further include a fraction of the fermented notoginseng root extract. The term "fraction" refers to a substance of a component into which the fermented notoginseng root extract is divided, i.e., a substance that has been fractionated. The fraction may be obtained by solvent fractionation (fractionation). The solvent fractionation may be to mix the fermented notoginseng root extract with a solvent and separate substances present in the solvent. The fraction may be a dichloromethane fraction, an ethyl acetate fraction, a butanol fraction, or a water fraction obtained by suspending the fermented notoginseng root extract in water and then sequentially fractionating the suspended extract using dichloromethane, ethyl acetate, butanol, and water.
Specifically, the dichloromethane fraction may be obtained by mixing the fermented notoginseng root extract with water, mixing the mixture with dichloromethane again, standing for a certain time, then separating a dichloromethane layer, and separating a fraction from the separated dichloromethane layer. The separation of the fractions may include removing dichloromethane from the dichloromethane layer. Further, the ethyl acetate fraction may be one obtained by mixing water remaining after the separation of the dichloromethane fraction again with ethyl acetate, standing for a certain time, then separating an ethyl acetate layer, and separating a fraction from the separated ethyl acetate layer. The separation of the fractions may include removing ethyl acetate from the ethyl acetate layer. In addition, the butanol fraction may be obtained by mixing water remaining after separating the ethyl acetate fraction with butanol again, standing for a certain time, separating a butanol layer, and separating a fraction from the separated butanol layer. The separation of the fraction may include removing butanol from the butanol layer. The conditions of the fractionation, such as temperature conditions, pressure conditions, time, amount or concentration of solvent used, stirring, and the like, may be the same as described with respect to the extraction for preparing the fermented notoginseng root extract. The fractionation may be repeated more than once, for example 1 to 5 times.
The separation of the fractions may be accomplished by known methods such as filtration. The fractionation may also include removing the solvent from the resulting fraction by a known method such as concentration under reduced pressure. The fractionation may also include concentrating and/or drying the resulting fraction. The concentration may be concentration under reduced pressure. The drying may include drying under reduced pressure, boiling dry, spray drying, drying at room temperature, or freeze drying.
The composition according to an embodiment may increase the expression of at least one selected from the group consisting of type i collagen α 1(alpha-1type 1collagen, COL1a1), fibrin 1(fibrillin 1, FBN1) and elastin (elastin, ELN), and particularly, may exhibit effects of improving skin wrinkles, enhancing skin elasticity and inhibiting skin aging by increasing the expression of COL1a1, FBN1 and ELN.
A composition according to a particular embodiment may comprise an effective amount of the extract or comprise the extract as an active ingredient. The effective amount may be appropriately selected depending on the individual. The effective amount may be determined based on factors including the following, as well as other factors well known in the physiological to medical arts: severity of disease-to-condition (condition), age, weight, health, sex of the individual, sensitivity of the individual to the extract, time of administration, route and rate of excretion, period of administration, other compositions used in conjunction or concomitantly with the composition.
The composition for improving skin beauty according to an embodiment may further include a cosmetically, dietetically or pharmaceutically acceptable excipient or carrier. The carrier may be an excipient, disintegrant, binder, lubricant, or combination thereof. The excipient may be microcrystalline cellulose, lactose, low substituted hydroxycellulose, or a combination thereof. The disintegrant may be sodium starch glycolate, anhydrous dibasic calcium phosphate, or a combination thereof. The binder may be polyvinylpyrrolidone, low-substituted hydroxypropylcellulose, or a combination thereof. The lubricant may be magnesium stearate, silicon dioxide, talc, or a combination thereof.
The formulation type of the composition may be a non-oral administration dosage form. The non-oral administration dosage form may be an injection or a skin external preparation. The skin external agent can be cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, medicated bandage, lotion or their combination.
The skin external preparation may be appropriately mixed with ingredients of skin external preparations generally used in cosmetics, pharmaceuticals, and the like, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, ultraviolet absorbers, whitening agents, preservatives, antioxidants, surfactants, perfumes, colorants, various skin nutrients, and the like, as necessary.
The skin external preparation can be mixed with appropriate amount of disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, metal chelating agent such as gluconic acid, caffeine, tannin, verapamil, Glycyrrhrizae radix extract, glabridin, hot water extract of Cirsium japonicum fruit, various crude drugs, tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts, and saccharides such as vitamin C, magnesium ascorbyl phosphate, ascorbyl glucoside, arbutin, kojic acid, glucose, fructose, and trehalose.
The composition according to a particular embodiment may be a cosmetic composition. At this time, the extract may be prepared into a dosage form including: lotions (lotions), emollients, lotions, astringents (astringents), lotions, milk lotions (milk lotions), moisturizing lotions, nutritional liquids, massage creams, nutritional creams, moisturizing creams, hand creams, foundations, essences, nutritional essences, films, soaps, facial foams, facial cleansers, body lotions, body cleansers, suspensions, gels, powders, pastes (pastes), masks or sheet masks, or spray compositions. Compositions of such dosage forms may be prepared according to methods conventional in the art. The cosmetic composition may further comprise preservatives, stabilizers, surfactants, solvents, moisturizers, emollients, ultraviolet absorbers, preservatives, bactericides, antioxidants, pH adjusters, organic and inorganic pigments, fragrances, cold sensates or antiperspirants. The mixing amount of the additional ingredients such as the humectant and the like can be easily selected by those skilled in the art within a range not impairing the object and effect of the present invention, and can be 0.001% to 5%, specifically, 0.01% to 3%, based on the total weight of the composition.
The composition according to a particular embodiment may be a food composition. At this time, a formulation of a conventional health food known in the art may be prepared. The food composition may be prepared in the general dosage forms such as powder, granule, tablet, pill, capsule, suspension, oil, syrup, maceration, liquid, extractant, etc., and in any health food forms such as meat, sausage, bread, chocolate, candy, snack, biscuit, pizza, stretched noodles, other noodles, chewing gum, jelly, dairy products including ice cream, various soups, beverages, tea, drinkable preparation, alcoholic beverage, and vitamin complex. In order to formulate the health food, a dietetically acceptable carrier or additive may be used, and any carrier or additive known in the art may be used to prepare a formulation desired to be prepared. The additives may include various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectic acids and salts thereof, alginic acids and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents for carbonated beverages, and the like. In addition, the additives may include pulp for preparing natural fruit juice, fruit juice beverages, and vegetable beverages. These additive components may be used alone or in combination, and the proportion of the additive may be 0.001% to 5%, specifically 0.01% to 3%, based on the total weight of the composition.
The content of the extract in the food composition may be appropriately determined depending on the purpose of use (prevention or improvement). Generally, 0.01% to 15% by weight of the total weight of the food can be included, and when prepared as a beverage, a proportion of 0.02g to 10g, specifically, a proportion of 0.3g to 1g, can be contained on the basis of 100 mL.
The beverage may further include other ingredients than the extract, and may further include various flavors or natural carbohydrates, etc. generally used for beverages. The natural carbohydrate may include conventional sugars such as monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), polysaccharides (e.g., dextrin, cyclodextrin, etc.), and sugar alcohols such as xylitol, sorbitol, erythritol, etc. In addition, the flavors may include natural flavors (e.g., thaumatin, stevia extract, etc.) and synthetic flavors (e.g., saccharin, aspartame, etc.). The proportion of natural carbohydrates may typically be from about 1g to 20g, in particular from about 5g to 12g, per 100mL of beverage.
Another aspect of the present invention provides a method of improving the cosmetic appearance of skin of an individual comprising the step of applying the cosmetic, food composition to the individual. The composition is the same as described above.
In particular, the method may be a method of improving skin wrinkles, a method of enhancing skin elasticity, or a method of inhibiting skin aging in a subject.
The terms "administered," "introduced," and "transplanted" are used interchangeably and may refer to a method of achieving at least partial localization of a composition according to an embodiment to a desired site or to the placement of a composition according to an embodiment into an individual according to a route. The extract or at least a portion of the extract component of the composition according to a particular embodiment may be administered by any suitable route for delivery to a desired location in a living body.
Administration can be performed by any method known in the art. Administration can be carried out directly to the individual in any manner by routes such as intravenous, intramuscular, oral, transdermal, mucosal, intranasal, intratracheal, or subcutaneous administration. The use may be performed systemically or locally.
The subject may be a mammal, such as a human, cow, horse, pig, dog, sheep, goat or cat. The subject may be a subject in need of an improvement in skin beauty such as improvement in skin wrinkles, enhancement in skin screen elasticity, or an effect of suppressing skin aging.
The administering can be daily administering the fermented notoginseng root extract to the individual in the following amounts: 0.1mg to 1000mg, e.g., 0.1mg to 500mg, 0.1mg to 100mg, 0.1mg to 50mg, 0.1mg to 25mg, 1mg to 1000mg, 1mg to 500mg, 1mg to 100mg, 1mg to 50mg, 1mg to 25mg, 5mg to 1000mg, 5mg to 500mg, 5mg to 100mg, 5mg to 50mg, 5mg to 25mg, 10mg to 1000mg, 10mg to 500mg, 10mg to 100mg, 10mg to 50mg, or 10mg to 25 mg. However, the administration amount may be variously prescribed depending on factors such as formulation method, administration method, age, body weight, sex, pathological condition, diet, administration time, administration route, excretion rate, and response sensitivity of the patient, and the like, and those skilled in the art will understand that the administration amount may be appropriately adjusted in consideration of these factors. The number of administrations may be 1 time per day or 2 or more times within a clinically acceptable side effect range, with respect to the administration site, one or two or more administrations may be given, and the total number of administration days per day or every 2 to 5 days as an interval may be 1 to 30 days at the time of one treatment. If desired, the same treatment can be repeated after an appropriate time. For animals other than humans, the administration may be performed in the same amount as humans per kg of the administration amount, or in an amount converted to the administration amount by a volume ratio (for example, average value) of organs (heart and the like) of the target animal and humans, or the like.
Another aspect of the present invention provides a method for preparing a fermented notoginseng root extract, which comprises: fermenting notoginseng root using Aspergillus cristatus (Aspergillus cristatus) strain to prepare fermented notoginseng root; and contacting the fermented notoginseng root with a C1-C6 alcohol, water or a mixture thereof.
The Notoginseng radix root, Aspergillus crustis strain, fermented Notoginseng radix root and fermented Notoginseng radix extract are the same as above.
According to a method of a specific example, the strain may be Aspergillus cristatus (GF 8 strain) (accession No.: KCCM 12432P).
According to a method of a particular embodiment, the fermentation may be a solid fermentation.
According to a method of a specific embodiment, the fermentation may be performed at 25 ℃ to 35 ℃ for 1 day to 10 days.
The fermented notoginseng root extract prepared by the method can exhibit effects of improving skin wrinkles, enhancing skin elasticity, and inhibiting skin aging by increasing the expression of at least one selected from COL1a1, FBN1, and ELN. The fermented notoginseng root extract has obviously better effects of improving skin wrinkles, enhancing skin elasticity and inhibiting skin aging than the unfermented notoginseng root extract. Therefore, the fermented notoginseng root extract prepared by the method can be used for various purposes, such as cosmetics, foods, and the like.
Drawings
FIG. 1 is a photograph of fermented Panax notoginseng roots solid-cultured with Aspergillus curvatus (A. cristatus) GF8 strain (accession No.: KCCM 12432P).
FIG. 2 shows the results of liquid chromatography-mass spectrometry (LC-MS) of Notoginseng radix in comparative examples 1 and 2 and example 1. Comparative example 1: notoginseng radix extract; comparative example 2: fermenting with Aspergillus curassis GF8 strain liquid for 4 days to obtain Notoginseng radix extract; example 1: solid fermenting with Aspergillus curassis GF8 strain for 4 days to obtain Notoginseng radix extract.
Fig. 3 is LC-MS results of notoginseng roots of comparative example 1 and examples 2 to 5. Comparative example 1: notoginseng radix extract; example 2 to example 5: a notoginseng root extract is solid-fermented with Aspergillus curassis GF8 strain for 2 days (example 2), 4 days (example 3), 6 days (example 4) or 8 days (example 5).
FIG. 4 is a graph showing the relative mRNA level (relative level) of dermal component gene COL1A1 in Normal Human Dermal Fibroblasts (NHDF) of skin origin at 20 and 65 years old. None (None): a negative control group; liquid Fermentation (LF)0 days and solid fermentation (SSF)0 days: the notoginseng root extract treatment group of comparative example 1; LF 4 days: the liquid fermented notoginseng root extract treatment group of comparative example 2; SSF 4 days: the solid fermented notoginseng root treatment group of example 1.
Fig. 5 is a graph of the relative mRNA levels of dermal component gene FBN1 in 20 and 65 year old skin-derived NHDF cells. None: a negative control group; LF 0 and SSF 0 days: the notoginseng root extract treatment group of comparative example 1; LF 4 days: the liquid fermented notoginseng root extract treatment group of comparative example 2; SSF 4 days: the solid fermented notoginseng root treatment group of example 1.
Fig. 6 is a graph of the relative mRNA levels of the dermal component gene COL1a1 in 20 and 65 year old skin-derived NHDF cells. None: a negative control group; SSF 0 day: the notoginseng root extract treatment group of comparative example 1; SSF 2 days, SSF 4 days, SSF 6 days, and SSF8 days: the solid-state fermentation notoginseng root treatment groups of example 2 to example 5, respectively.
Fig. 7 is a graph of the relative mRNA levels of dermal component gene FBN1 in 20 and 65 year old skin-derived NHDF cells. None: a negative control group; SSF 0 day: the notoginseng root extract treatment group of comparative example 1; SSF 2 days, SSF 4 days, SSF 6 days, and SSF8 days: the solid-state fermentation notoginseng root treatment groups of example 2 to example 5, respectively.
Fig. 8 is a graph of the relative mRNA levels of dermal component gene ELN in 20 and 65 year old skin-derived NHDF cells. None: a negative control group; SSF 0 day: the notoginseng root extract treatment group of comparative example 1; SSF 2 days, SSF 4 days, SSF 6 days, and SSF8 days: the solid-state fermentation notoginseng root treatment groups of example 2 to example 5, respectively.
Detailed Description
Hereinafter, the present disclosure will be described in more detail by examples. However, these embodiments are for the purpose of describing the present disclosure, and the scope of the present disclosure is not limited to these embodiments.
Comparative example 1: preparation of pseudo-ginseng root extract
The method comprises collecting 300g of Notoginseng radix (produced in Yunnan, China, available from Torrel Jingdong, Korea) and washing, adding water to make the water content of Notoginseng radix 45%, and soaking for 2 hr. Placing the Notoginseng radix with water into a metal sieve, and sterilizing at 121 deg.C for 60 min. Freeze-drying until the final water content is 12%, and pulverizing. 200mL of 80% ethanol was added to 200g of the pulverized sample, and the mixture was sonicated for 10 minutes, and then stirred in a rotary shaker at 200rpm for 24 hours and extracted. Then the extract is added intoCentrifuging at 4 deg.C and 2370G for 10 min, and filtering the supernatant with 0.22 μm filter (C)Merck Millipore, usa). The filtered supernatant was dried in a vacuum concentrator, and then the dry weight was measured for use.
Comparative example 2: preparation of Liquid Fermentation (LF) Notoginseng radix extract
300g of the same notoginseng root as described in comparative example 1 was taken, washed and pulverized, and then 1.2L of distilled water was added and sterilized at 121 ℃ for 60 minutes. Then, an Aspergillus cristatus (Aspergillus cristatus) GF8 strain grown in a Potato Dextrose Agar (PDA) medium was made into a spore suspension, which was inoculated into a solution containing sterile notoginseng roots and liquid-fermented at 30 ℃ for 4 days. Freeze-drying until the final water content is 12%, and pulverizing. 200mL of 80% ethanol was added to 200g of the pulverized sample, and the mixture was sonicated for 10 minutes, and then stirred in a rotary shaker at 200rpm for 24 hours and extracted. The extract was centrifuged and filtered and the supernatant was dried in the same manner as described in comparative example 1, and then the dry weight was measured for use.
Example 1: preparation of Solid State Fermentation (SSF) Notoginseng radix extract
In the same manner as described in comparative example 1, 2X 105A suspension of CFU (colony-forming unit)/mL of Aspergillus curdatus GF8 spores was inoculated into sterilized Notoginseng radix roots and cultured at 30 ℃ for 4 days to perform solid fermentation. Then freeze-dried until the final moisture content is 12% and pulverized. 200mL of 80% ethanol was added to 200g of the pulverized sample, and the mixture was sonicated for 10 minutes, and then stirred in a rotary shaker at 200rpm for 24 hours and extracted. The extract was centrifuged and filtered and the supernatant was dried in the same manner as described in comparative example 1, and then the dry weight was measured for use.
Example 2 to example 5: preparation of solid fermented notoginseng root extract
A solid fermented notoginseng root extract was prepared in the same manner as described in example 1, except that after the aspergillus papulosus GF8 spore suspension was inoculated to the sterilized notoginseng root, it was cultured at 30 ℃ for 2 days (example 2), 4 days (example 3), 6 days (example 4) or 8 days (example 5).
Preparation example 1: preparation of essence formulation added with notoginseng root or fermented notoginseng root extract
The essence formulation was prepared according to the composition and content of table 1 below by a conventional method.
[ TABLE 1 ]
Experimental example 1: liquid chromatography-mass spectrometry analysis of solid fermented pseudo-ginseng root metabolites
The change pattern of the pseudo-ginseng root metabolites after solid fermentation is researched by liquid chromatography-mass spectrometry (LC-MS).
Specifically, LC-MS analysis was performed using a UHPLC (Ultra-high-performance LC) mass spectrometer (UHPLC-Orbitrap-IT-MS/MS, Thermo Fisher Scientific, USA). The samples of comparative example 1, comparative example 2 and examples 1 to 5 were injected into a chromatography column (Hypersil Gold C18 column) at a rate of 0.3mL/min by 5. mu.L each, and the mobile phase consisted of solution A (0.1% (v/v) aqueous formic acid solution) and solution B (0.1% (v/v) acetonitrile formate solution), and the temperature of the Probe heater (Probe heater) was adjusted to 300 ℃ for analysis. The LC-MS patterns obtained from the analysis results are shown in fig. 2 and 3.
As a result, as shown in fig. 2, it can be seen that the notoginseng root metabolites vary depending on the fermentation method, i.e., liquid fermentation or solid fermentation. In addition, as shown in fig. 3, it can be seen that the notoginseng root metabolites vary according to the fermentation time in the solid fermentation.
Experimental example 2: confirming the Gene expression increasing action of dermal Components in solid fermented Panax notoginseng root
To confirm the gene expression increasing effect of the solid-fermented notoginseng root dermal components of the skin, real-time Polymerase Chain Reaction (PCR) was performed.
Specifically, Normal Human Dermal Fibroblasts (NHDF) collected from human skin of 20 and 65 years old were treated at 3.5X 105The density of individual cells/well was plated in 6-well plates and incubated at 37 ℃ in an incubator with 5% carbon dioxide for 24 hours. Next, after removing the medium and washing with Dulbecco's Phosphate-Buffered Saline (DPBS) and changing to serum-free (serum) -medium, 10. mu.g/mL of each of the samples of comparative example 1, comparative example 2 and examples 1 to 5 was treated for further culture for 24 hours.
Then, the cells were recovered with Accutase (Merck, USA), and the cell recovery kit (RNAprep, USA) was usedTotal RNAprep Kit, NEB, USA) to isolate RNA. After quantification of the isolated RNA at 260nm using NanoDrop, 2. mu.g of RNA was synthesized into complementary DNA (cDNA) using an amplification instrument (C1000Thermal Cycler, Bio-Rad, USA). Each of the synthesized cDNAs was mixed with the primers and SYBR-Green mixture (SYBR-Green supermix, Applied Biosystems, USA) of Table 2 below to perform real-time PCR. The real-time PCR reaction was performed for 40 cycles under the following conditions: after 5 minutes of polymerase activation at 94 ℃, polymerase activation was carried out for 30 seconds at 95 ℃, 30 seconds at 55 ℃ and 30 seconds at 72 ℃.
[ TABLE 2 ]
Relative mRNA levels of each of collagen type i α 1(alpha-1type 1collagen, COL1a1), fibrin 1(fibrillin 1, FBN1) and elastin (elastin, ELN) genes as human dermal components were corrected and analyzed based on mRNA expression amounts of β -actin (β -actin) genes, as shown in fig. 4 to 8.
As a result, as shown in fig. 4 and 5, it was confirmed that the relative mRNA expression amounts of COL1a1 and FBN1 in solid fermented notoginseng root (example 1) were significantly higher than those of notoginseng root (comparative example 1) and liquid fermented notoginseng root (comparative example 2) in both cells, and that the mRNA expression of COL1a1 and FBN1 was increased to a level similar to that of the control group of 25-year-old-derived NHDF cells in the naturally-aged 65-year-old-derived NHDF cell group treated with solid fermented notoginseng root.
In addition, as shown in fig. 6 and 7, the mRNA expression of COL1a1 and FBN1 was increased in notoginseng roots (examples 2 to 5) that were solid-fermented for 2 days, 4 days, or 6 days in 20-year-old-derived NHDF cells and in notoginseng roots (examples 2 to 5) that were solid-fermented for 2 days, 4 days, 6 days, or 8 days in 65-year-old-derived NHDF cells, as compared to notoginseng roots (comparative example 1) before fermentation.
As shown in fig. 8, mRNA expression of ELN was increased in the notoginseng roots that were solid-fermented for 2 days, 4 days, 6 days, or 8 days in 20-year-old-derived NHDF cells (examples 2 to 5) and in the notoginseng roots that were solid-fermented for 4 days, 6 days, or 8 days in 65-year-old-derived NHDF cells (examples 3 to 5), as compared to the notoginseng roots before fermentation (comparative example 1).
That is, as can be seen from the results shown in fig. 6 to 8, the expression increasing patterns of COL1a1, FBN1 and ELN are different depending on the solid fermentation time of notoginseng root, and the effect is excellent particularly in notoginseng root which is solid-fermented for 4 days or 6 days.
According to a composition for improving skin beauty in one aspect of the present invention, the use of fermented notoginseng root extract fermented with aspergillus guani (a. cristatus) strain can improve skin wrinkles, enhance skin elasticity, inhibit skin aging.
According to the method for preparing the fermented notoginseng root extract according to another aspect of the present invention, the fermented notoginseng root extract having the effect of improving skin beauty can be prepared, and the prepared extract can be applied to various fields such as cosmetics and foods.
Claims (17)
1. A cosmetic composition for improving skin beauty comprises a fermented Panax notoginseng root extract obtained by fermenting Panax notoginseng root with a strain of Aspergillus coronarius as an effective ingredient.
2. The composition according to claim 1, wherein the improvement in skin beauty is improvement in skin wrinkles, enhancement in skin elasticity or inhibition of skin aging.
3. The composition according to claim 1, wherein the strain is Aspergillus papulosus GF8 strain (accession No: KCCM 12432P).
4. The composition of claim 1, wherein the fermentation is a solid fermentation.
5. The composition of claim 1, wherein fermenting the notoginseng root is carried out for 1 to 10 days.
6. The composition of claim 1, wherein the fermenting notoginseng root is performed at 25 ℃ to 35 ℃.
7. The composition of claim 1, wherein the extract is an extract of C1-C6 alcohol, water, or a mixture thereof.
8. The composition of claim 1, wherein the extract is an ethanol extract.
9. The composition of claim 1, wherein the extract is present in an amount of 0.001% to 10% based on the total weight of the composition.
10. The composition of claim 1, wherein the composition increases the expression of at least one selected from the group consisting of type i collagen alpha 1, fibrin 1, and elastin.
11. The composition according to claim 1, which is prepared in at least one formulation selected from the group consisting of a lotion, a smoothing lotion, a toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nutrient solution, a massage cream, a nutrient cream, a moisturizing cream, a hand cream, a foundation, an essence, a nutrient essence, a film, a soap, a cleansing foam, a cleansing milk, a cleansing cream, a body lotion, a body cleaning solution, a suspension, a gel, a powder, a stick, a pack or a sheet pack, or a spray composition.
12. A food composition for improving skin beauty comprises a fermented Panax notoginseng root extract obtained by fermenting Panax notoginseng root with a strain of Aspergillus coronarius as an effective ingredient.
13. A method for preparing a fermented Panax notoginseng root extract, comprising:
fermenting Notoginseng radix with Monascus coronarius strain to obtain fermented Notoginseng radix; and
contacting said fermented notoginseng root with a C1-C6 alcohol, water or a mixture thereof.
14. The method according to claim 13, wherein the strain is Aspergillus papulosus GF8 strain (accession No: KCCM 12432P).
15. The method of claim 13, wherein the fermentation is a solid fermentation.
16. The method of claim 13, wherein the fermentation is performed for 1 to 10 days.
17. The method of claim 13, wherein the fermentation is performed at 25 ℃ to 35 ℃.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0105186 | 2019-08-27 | ||
KR1020190105186A KR102239415B1 (en) | 2019-08-27 | 2019-08-27 | Composition for improving skin beauty comprising extract of fermented roots of Panax notoginseng by Aspergillus cristatus strain |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112438921A true CN112438921A (en) | 2021-03-05 |
CN112438921B CN112438921B (en) | 2022-07-29 |
Family
ID=74733217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010275128.4A Active CN112438921B (en) | 2019-08-27 | 2020-04-09 | Composition for improving skin beauty comprising fermented notoginseng root extract obtained from aspergillus guaneus |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102239415B1 (en) |
CN (1) | CN112438921B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249233A (en) * | 2021-06-29 | 2021-08-13 | 北京百奥茵诺生物科技有限公司 | Eurotium cristatum and microbial inoculum and application thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102681194B1 (en) * | 2022-11-02 | 2024-07-03 | 주식회사 래디안 | Cosmetic compostion comprising phellodendron amurense extract for inhibiting skin glycation |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825383A (en) * | 2015-05-28 | 2015-08-12 | 云南白药集团股份有限公司 | Pseudo-ginseng yeast extraction method and application |
CN107233244A (en) * | 2017-06-08 | 2017-10-10 | 无限极(中国)有限公司 | A kind of preparation method and applications of Sanqi fermentation liquor |
KR20180114785A (en) * | 2017-04-11 | 2018-10-19 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of fermented ginseng fermented with Aspergillus cristatus strain |
KR102009633B1 (en) * | 2019-02-18 | 2019-08-13 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of solid state fermented ginseng by Aspergillus cristatus strain |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101419463B1 (en) | 2012-04-10 | 2014-07-14 | 신준식 | Herbal composition for prevention and treatment of hepatic disease |
-
2019
- 2019-08-27 KR KR1020190105186A patent/KR102239415B1/en active IP Right Grant
-
2020
- 2020-04-09 CN CN202010275128.4A patent/CN112438921B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825383A (en) * | 2015-05-28 | 2015-08-12 | 云南白药集团股份有限公司 | Pseudo-ginseng yeast extraction method and application |
KR20180114785A (en) * | 2017-04-11 | 2018-10-19 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of fermented ginseng fermented with Aspergillus cristatus strain |
CN107233244A (en) * | 2017-06-08 | 2017-10-10 | 无限极(中国)有限公司 | A kind of preparation method and applications of Sanqi fermentation liquor |
KR102009633B1 (en) * | 2019-02-18 | 2019-08-13 | 코스맥스 주식회사 | Composition for improving skin beauty comprising extract of solid state fermented ginseng by Aspergillus cristatus strain |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249233A (en) * | 2021-06-29 | 2021-08-13 | 北京百奥茵诺生物科技有限公司 | Eurotium cristatum and microbial inoculum and application thereof |
CN113249233B (en) * | 2021-06-29 | 2021-11-09 | 北京百奥茵诺生物科技有限公司 | Eurotium cristatum and microbial inoculum and application thereof |
Also Published As
Publication number | Publication date |
---|---|
KR102239415B1 (en) | 2021-04-13 |
CN112438921B (en) | 2022-07-29 |
KR20210025316A (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102009633B1 (en) | Composition for improving skin beauty comprising extract of solid state fermented ginseng by Aspergillus cristatus strain | |
KR101811034B1 (en) | COMPOSITION FOR WHITENING CONTAINING Fermented Castanea crenata inner shell extracts | |
CN110278706B (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with strain of Aspergillus coronarius | |
CN111434652B (en) | Diuracil, use thereof and method for producing same | |
CN112438921B (en) | Composition for improving skin beauty comprising fermented notoginseng root extract obtained from aspergillus guaneus | |
KR20210025317A (en) | A genus of Staphylococcus strain and uses thereof | |
KR102239784B1 (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR102019642B1 (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
KR101963572B1 (en) | Composition for improving skin beauty comprising extract of fermented swallow's nest fermented with Aspergillus cristatus strain | |
KR102004150B1 (en) | Composition for improving skin beauty comprising extract of fermented ginseng fermented with Aspergillus cristatus strain | |
KR102046298B1 (en) | Composition for improving skin beauty comprising extract of fermented Lentinula edodes fermented with Aspergillus cristatus strain | |
KR102484422B1 (en) | Cosmetic composition comprising extract of Cactus and fermented product of Lactobacillus | |
KR102361015B1 (en) | Use of Sphingomonas olei to improve skin condition | |
KR20230095471A (en) | Composition for improving muscle strength comprising fermented Schisandra chinensis fruit byproduct and method for preparing the same | |
KR101718351B1 (en) | Novel Paenibacillus sp. RMKS 72, fermented ginseng using the same and composition having anti-oxidant activity comprising extract of fermented ginseng using the same | |
EP3127547B1 (en) | Composition comprising extract of alpine wormwood | |
KR102224313B1 (en) | Composition for skin whitening comprising scutellaria alpina extract | |
KR101994618B1 (en) | A composition for skin smoothing comprising an extract of fermented ponciri fructus | |
KR102037039B1 (en) | Composition comprising flocculin for improving skin condition | |
KR20190089696A (en) | A skin whitening composition comprising Cimicifuga dahurica extract or an active ingredient isolated therefrom as an active ingredient | |
KR102411240B1 (en) | Use of Phycicoccus jejuensis to improve skin condition | |
KR102249431B1 (en) | Composition for treating alopecia comprising Cocos nucifera extract | |
KR102687359B1 (en) | Novel Scalp-derived Lacticaseibacillus rhamnosus sc.Q5 strain having hair growth promotion effect and use thereof | |
EP4082554A1 (en) | Composition for use in inhibiting lipofuscin accumulation or removing lipofuscin | |
EP3895687A1 (en) | Composition comprising allulose as active ingredient for skin whitening |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |